Restructuring On The Table For FibroGen After Roxadustat Rejection
Executive Summary
As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.